Inhibition of mitochondrial permeability transition pore opening: translation to patients.
about
Translation of TRO40303 from myocardial infarction models to demonstration of safety and tolerance in a randomized Phase I trialMitochondrial targets for pharmacological intervention in human diseaseExperimental treatments for mitochondrial dysfunction in sepsis: A narrative reviewAttenuation of skeletal muscle and renal injury to the lower limb following ischemia-reperfusion using mPTP inhibitor NIM-811The role of oxidized cytochrome c in regulating mitochondrial reactive oxygen species production and its perturbation in ischaemiaPotential therapeutic benefits of strategies directed to mitochondria.Mitochondrial approaches to protect against cardiac ischemia and reperfusion injury.Effects of Cyclosporine on Reperfusion Injury in Patients: A Meta-Analysis of Randomized Controlled Trials.Cockayne syndrome group B protein prevents the accumulation of damaged mitochondria by promoting mitochondrial autophagy.Inorganic polyphosphate is a potent activator of the mitochondrial permeability transition pore in cardiac myocytes.Cyclosporin variably and inconsistently reduces infarct size in experimental models of reperfused myocardial infarction: a systematic review and meta-analysis.Increase in Cardiac Ischemia-Reperfusion Injuries in Opa1+/- Mouse Model.Na(+)/Ca(2+) exchanger 1 (NCX-1) mediates the anti-apoptotic effect of Akt1 in neonatal rat cardiomyocytes during ischemia/reperfusion.Mechanisms of mitochondrial damage in keratinocytes by pemphigus vulgaris antibodies.Intralipid, a clinically safe compound, protects the heart against ischemia-reperfusion injury more efficiently than cyclosporine-A.Mechanism of cardioprotection by early ischemic preconditioningAutophagy: definition, molecular machinery, and potential role in myocardial ischemia-reperfusion injury.There is more to life than revascularization: therapeutic targeting of myocardial ischemia/reperfusion injury.Efficacy of cardioprotective 'conditioning' strategies in aging and diabetic cohorts: the co-morbidity conundrum.Mitochondria, calcium-dependent neuronal death and neurodegenerative disease.Heart transplantation with donation after circulatory determination of death.The role of hexokinase in cardioprotection - mechanism and potential for translation.Cyclosporine A attenuates apoptosis and necrosis after ischemia-reperfusion-induced renal injury in transiently hyperglycemic rats.Long-term oral resveratrol intake provides nutritional preconditioning against myocardial ischemia/reperfusion injury: involvement of VDAC1 downregulation.Remote ischaemic pre- and delayed postconditioning - similar degree of cardioprotection but distinct mechanisms.Effects of sphingosine-1-phosphate on acute contractile heart failure (ACHF).Cyclosporine A cardioprotection: mechanisms and potential for clinical application.Cardioprotection by curcumin post-treatment in rats with established chronic kidney disease.Avoidance of Profound Hypothermia During Initial Reperfusion Improves the Functional Recovery of Hearts Donated After Circulatory Death.Autoimmunity against cardiac troponin I in ischaemia reperfusion injury.Mitochondria in Cardiac Postconditioning.Transplantation of Hearts Donated after Circulatory Death.
P2860
Q21245483-44803B21-31B2-40EA-ACB7-3EA3BC9531C2Q26824514-F459EF97-6F64-4E37-8CC5-388E91F0921DQ28392010-2949D509-2AA5-4A87-9D52-61101698F6C2Q28540094-615B1608-BD6F-4294-9331-FA6CC850D44CQ28568843-E5F2CF82-D76F-40DC-BFA5-E90318D2DE25Q34117168-DE046DAF-D01C-4F4B-81E8-53290262B160Q34854255-32470392-7B15-4CFF-A126-B74D5347A1AFQ35806794-0DB263F2-A330-4FB0-8C95-B86AC0B2A314Q35894155-F503654C-8160-43F8-BBF7-4B9D591FD68CQ35931855-AC16CF21-06E8-4486-AD7D-8B509986DB4FQ36147255-204DD75D-8384-40D7-B74F-89E2EB7E3B05Q36159289-AE654ABC-8B45-4CED-BDFD-807DAA96EEF5Q36878548-7BDBE4D3-8778-45D4-B15E-82C9DFB517A4Q36910181-24A733FD-0CE9-4FB6-A788-2A7CE3A25970Q37160450-F408C33C-7B97-4E68-AB20-141C315CE28FQ37761070-620625A8-FBD9-420F-9178-ED3B675DB02FQ37769377-FD3AA60C-EF69-4809-8A0B-F5E1A46A4A6EQ37774394-0720FCA1-1152-4035-B406-A8F6C7755991Q37871976-896FB230-2F5B-4663-A694-D648832C8AF0Q38012067-371BE8CA-3E9A-48AA-95E5-B9920461D746Q38204894-785B1AAB-FB72-4B2E-8B14-494658D4BBCAQ38247510-34895D14-0388-44D9-879D-61BC5DFF8254Q38840106-994FA2C1-0EF5-4992-8738-B9B6664B46D0Q41713887-3922BDCA-D611-4AB8-A064-5116F041FB21Q42091617-C88418AF-03C1-4A60-83E1-6B55FA49729BQ42908279-C07A5C83-60E9-41DE-BB83-2DBA2736B56CQ43086748-3573085D-F861-450F-BB3B-9D25E1F17A82Q46758479-F48AA537-8174-4FCA-92DB-A27070125342Q47602043-2646CFE8-6462-4241-BD72-23677DA59557Q54355654-C45798BA-2A16-4EE2-8697-248549065131Q54943876-F898DEDE-04CB-4631-AFEA-56266E180DE8Q55296393-441D6E6D-0815-45B3-8590-4B5892AFB434
P2860
Inhibition of mitochondrial permeability transition pore opening: translation to patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Inhibition of mitochondrial pe ...... ning: translation to patients.
@en
Inhibition of mitochondrial pe ...... ning: translation to patients.
@nl
type
label
Inhibition of mitochondrial pe ...... ning: translation to patients.
@en
Inhibition of mitochondrial pe ...... ning: translation to patients.
@nl
prefLabel
Inhibition of mitochondrial pe ...... ning: translation to patients.
@en
Inhibition of mitochondrial pe ...... ning: translation to patients.
@nl
P2093
P356
P1476
Inhibition of mitochondrial pe ...... ning: translation to patients.
@en
P2093
Christophe Piot
Ingrid Sanchez
Ludovic Gomez
Meier Elbaz
Michel Ovize
Nathan Mewton
P304
P356
10.1093/CVR/CVP063
P577
2009-02-16T00:00:00Z